A Canadian researcher won a 2025 Revolutionary Prize in Life Sciences For having discovered the GLP -1 hormone used in diabetes and obesity drugs – including Ozempic, Wegovy and Mounjaro – who have changed the lives of millions of people around the world.
Dr. Daniel Drucker, a researcher in endocrinology at the University of Toronto, said that he had spent 40 years discovering hormone’s ability to stimulate weight loss and stimulate insulin production to treat diabetes.
Drucker shares a price worth $ 3 million US with four colleagues from the United States and Denmark who were also involved in the GLP1 trip from the laboratory to pharmacies.
He said that it is rewarding to see him lead drugs that help people live with obesity to lose weight and live a healthy life.
Drucker says research now shows that GLP1 drugs can help reduce heart attacks, cerebral vascular accidents and death by cardiovascular disease.
He said there are also promising research suggesting that this could reduce inflammation and possibly treat arthritis, kidney disease and Alzheimer’s disease.
Get health news on health
Receive the latest medical information and health information provided to you every Sunday.
Another Canadian, Maaike Van Kooten from the National Research Council Canada, shared a price of US $ 100,000 called New Horizons in physics with two international colleagues to work in optics to see exoplanets.
Revolutionary prices – often called Oscars of Science – were awarded during a ceremony in Los Angeles on Saturday.
The Breakthrough Foundation said the prices were created to “celebrate the wonders of our scientific age”.
In an interview in the week before the event, Drucker said that the price was significant because it is awarded by other scientists and “attracts a lot of attention in the scientific community”.
“We have students and trainees and prices like this tell them that the world is watching and thinks that work is meritorious. And I think it’s just great for morale and for young people,” he said.
Drucker started his journey to study the genetic sequencing of glucagon type peptides in a laboratory in Boston in the 1980s, then returned to Canada and continued his work at the University of Toronto.
& Copy 2025 the Canadian press